Faustus Forschungs Cie, Translational Cancer Research Gmbh

Niiki Pharma Inc.

Bernhard Keppler

The invention relates to the use of gallium (III) complexes for the treatment of melanomas.

Use of gallium(III) complexes for the treatment of melanomas

The invention relates to a composition (A), obtained by reacting a compound of the general formula (I)M[RuXB(HO)(OH)(O)]&#x2003;&#x2003;(I)

Anticancer compositions, and methods of making and using the same

Compositions, containing a ruthenium(III) complex and a heterocycle, methods for their manufacture, medicament containing these compositions and a kit. The invention relates to a composition (A), obtained by reacting a compound of the general formula (I)M[RUXB(HO)(OH)(O)]&#x2003;&#x2003;(I) Furthermore, the invention relates to a composition (B), obtained by mixing a compound of the general formula (III)(B'H)[RUXB(HO)(OH)(O)]&#x2003;&#x2003;(III)

Compositions, containing a ruthenium(III) complex and a heterocycle, methods for their manufacture, medicament containing these compositions and a kit. The invention relates to a composition (A), obtained by reacting a compound of the general formula (I)M[RuXB(HO)(OH)(O)]&#x2003;&#x2003;(I) Furthermore, the invention relates to a composition (B), obtained by mixing a compound of the general formula (III)(B'H)[RuXB(HO)(OH)(O)]&#x2003;&#x2003;(III)

Compositions containing a ruthenium(III) complex and a heterocycle

Lanthanum compounds are provided having general formulas (I) RYand (II) RYwhich may be used as medicaments in the prophylaxis and/or treatment of cancer diseases. In formula (I), R is a group of general formula (A): and in general formula (II) Ris a group of general formula (B): 

Cytostatic lanthanum compounds

A tumor-inhibiting platinum (II) oxalate complex and its use as a therapeutic agent are provided, in particular as a tumor-inhibiting medicament. The complex may be compounds of the general formula (I), wherein the substituents R, R, R, R, R, R, R, and Rare independently selected from the group consisting of hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted cycloalkenyl, unsubstituted or substituted aryl and unsubstituted or substituted alkylaryl radicals, the substituents R, R, R, and Rare independently selected from the group consisting of hydrogen, unsubstituted or substituted alkyl, and unsubstituted or substituted alkenyl radicals, and wherein optionally in each case at least two of the substituents R, R, R, R, R, R, R, and Rcan form with one another at least one unsubstituted or substituted alkylene, unsubstituted or substituted alkenylene radical or an unsubstituted or substituted aromatic ring, and wherein optionally at least one of the carbon atoms of the cyclohexane ring bearing the substituents R, R, R, R, R, R, R, and Ris replaced by a heteroatom, and if the heteroatom is oxygen, the substituents R, R, R, R, R, R, R, and Rcan additionally be hydroxy radicals, and pharmaceutically compatible salts of them, provided that at least one of the substituents R, R, R, R, R, R, R, or Ris not equal to hydrogen and the substituents Ror Rand Ror Rdo not form any unsubstituted C-alkylene radical with one another.

Tumor-inhibiting platinum (II) oxalate complexes

The invention relates to a compound of the general formula (I)

Tumor inhibiting gallium compounds

The invention relates to cerium compounds having general formulas (I) RYand (II) RYand their application as medicaments in the prophylaxis and/or treatment of cancer diseases. In formula (I), R is a group of general formula (A):and in formula (II), Ris a group of general formula (B)

Growing community of inventors

Hockenheim, Germany

Bernhard Keppler